ASCO: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumors
Reports and Proceedings
Updates every hour. Last Updated: 8-Jul-2025 09:10 ET (8-Jul-2025 13:10 GMT/UTC)
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen compared to standard therapy in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Results from second interim analysis, presented at the 2025 ASCO Annual Meeting, show that the investigational combination doubled overall survival compared with standard-of-care (30.3 months versus 15.1 months). It also reduced the risk of death by half in patients who received the new combination.
A newly identified centromeric structure, the CENP-A–H4 octasome, may reveal how chromosomes segregate properly during cell division, report researchers from Japan. Using cryo-electron microscopy, they visualized this complex formed only of histones CENP-A and H4, wrapped around 120 base pairs of DNA, revealing unique features important for mitosis. These findings may provide a novel perspective for understanding diseases caused by abnormal cell division, including cancer.
Researchers trace the evolutionary history of the PD-1 immune checkpoint system across jawed vertebrates, uncovering conserved features with potential relevance for cancer immunotherapy.
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings, titled “Escalating Impact of Alcohol-Related Cancer Mortality in the U.S.: A call for action,” will be presented May 31 at ASCO 2025.
A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene promotes and sustains lymphoma development and progression, paving the way for novel targeted therapies.